ストックスクリーナーアプリを入手
18.05
3.32%
0.58
アフターアワーズ：
18.82
0.77
+4.27%
前日終値:
$17.47
開ける：
$17.33
24時間の取引高:
1.38M
Relative Volume:
1.50
時価総額：
$1.92B
収益：
$247.00M
当期純損益:
$-249.00M
株価収益率:
-5.8414
EPS:
-3.09
ネットキャッシュフロー:
$-267.00M
1週間 パフォーマンス:
+15.56%
1か月 パフォーマンス:
+45.68%
6か月 パフォーマンス:
+134.11%
1年 パフォーマンス:
+6.36%
1日の値動き範囲:
$17.02
$18.42
1週間の範囲:
$15.38
$18.42
52週間の値動き範囲:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
名前
Arcus Biosciences Inc
セクター
電話
(510) 694-6200
住所
3928 POINT EDEN WAY, HAYWARD, CA
RCUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
18.05 | 1.86B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.27 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
474.00 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.34 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
834.75 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.31 | 35.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 開始されました | H.C. Wainwright | Neutral |
| 2024-10-08 | 開始されました | Wells Fargo | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-11-23 | 開始されました | Evercore ISI | Outperform |
| 2020-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-09-27 | 開始されました | Mizuho | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2018-10-09 | 開始されました | Wedbush | Outperform |
| 2018-04-09 | 開始されました | Citigroup | Buy |
| 2018-04-09 | 開始されました | Goldman | Neutral |
| 2018-04-09 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Arcus Biosciences Inc (RCUS) 最新ニュース
Using AI based signals to follow Arcus Biosciences Inc.Weekly Volume Report & Entry Point Confirmation Signals - newser.com
Analyzing recovery setups for Arcus Biosciences Inc. investors2025 Valuation Update & Advanced Technical Analysis Signals - newser.com
Arcus Biosciences Inc. recovery potential after sell offMarket Performance Recap & Long-Term Safe Return Strategies - newser.com
Why Arcus Biosciences Inc. stock appears on watchlistsTrade Entry Report & Consistent Profit Alerts - newser.com
Is Arcus Biosciences Inc. stock safe for risk averse investorsQuarterly Market Review & Fast Gaining Stock Reports - newser.com
Should you hold or exit Arcus Biosciences Inc. nowEarnings Overview Report & Technical Pattern Based Signals - newser.com
Is this a good reentry point in Arcus Biosciences Inc.July 2025 Highlights & Entry Point Confirmation Signals - newser.com
How moving averages guide Arcus Biosciences Inc. tradingJuly 2025 WrapUp & Daily Volume Surge Signals - newser.com
RCUS: Wells Fargo Raises Price Target on Arcus Biosciences to $2 - GuruFocus
Published on: 2025-10-20 09:03:52 - newser.com
Applying sector rotation models to Arcus Biosciences Inc.Market Trend Summary & Daily Technical Forecast Reports - newser.com
Published on: 2025-10-20 00:14:27 - newser.com
Taiho Exercises Option for Casdatifan Development with Arcus (RC - GuruFocus
Will Arcus Biosciences Inc. stock benefit from sector rotationJuly 2025 PostEarnings & Verified Trade Idea Suggestions - newser.com
Exclusive license for casdatifan in Japan & select Asian territories — Taiho exercises option from Arcus - Stock Titan
Arcus Biosciences Hits Day High with Strong 8.19% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with 13.97% Surge Amid Market Decline - Markets Mojo
What analysts say about Arcus Biosciences Inc stockGlobal Trade Effects & Fast Growing Trading Plans - earlytimes.in
Visual analytics tools that track Arcus Biosciences Inc. performanceWeekly Risk Report & Verified Entry Point Signals - newser.com
Will Arcus Biosciences Inc. outperform the marketEarnings Growth Summary & Entry Point Strategy Guides - newser.com
Movement Recap: Will Arcus Biosciences Inc. stock benefit from sector rotation2025 Buyback Activity & AI Forecast Swing Trade Picks - nchmf.gov.vn
Can momentum traders help lift Arcus Biosciences Inc.Portfolio Profit Report & Fast Moving Stock Watchlists - newser.com
Why Arcus Biosciences Inc. stock is rated strong buyQuarterly Risk Review & Daily Chart Pattern Signal Reports - newser.com
Growth Recap: Will Arcus Biosciences Inc. stock benefit from sector rotationJuly 2025 Institutional & Risk Managed Investment Entry Signals - nchmf.gov.vn
Can Arcus Biosciences Inc. stock deliver consistent EPS growthJuly 2025 Earnings & Fast Gaining Stock Reports - nchmf.gov.vn
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets - Seeking Alpha
Arcus data throw TIGIT a lifeline: Clinical Report - biocentury.com
What dividend safety score for Arcus Biosciences Inc. stockMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Arcus Biosciences reports Phase 2 survival data for gastric cancer study - Investing.com Australia
Arcus’s ‘Last TIGIT Standing’ Shows Phase II Survival Benefit - Citeline News & Insights
Arcus Biosciences Reports Promising Phase 2 Study Results - TipRanks
Arcus Biosciences reports Phase 2 survival data for gastric cancer study By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (RCUS) 財務データ
収益
当期純利益
現金流量
EPS
2.32%
1.34%
大文字化:
|
ボリューム (24 時間):